Medicare Enrolled
Dr. Aftab Mahmood, M.D.
Optician · Corpus Christi, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Mahmood from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mahmood? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mahmood
Dr. Aftab Mahmood is an optician in Corpus Christi, TX, with 20 years in practice. Based on federal Medicare data, Dr. Mahmood performed 207,218 Medicare services across 2,406 unique beneficiaries.
Between the years covered by Open Payments, Dr. Mahmood received a total of $37,468 from 111 pharmaceutical and/or device companies across 1696 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mahmood is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 0% volume in TX$ $37,468 industry payments
Medicare Practice Summary
Medicare Utilization ↗207,218
Medicare services
Top 0% in TX for optician
2,406
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~10,361 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 64,770 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 37,080 | $18 | $93 |
| Iron infusion (Injectafer) | 25,500 | $1 | $5 |
| Pembrolizumab injection (Keytruda) | 23,800 | $42 | $220 |
| Oxaliplatin chemotherapy injection | 19,500 | $0 | $0 |
| Anti-nausea injection (fosaprepitant) | 11,850 | $0 | $1 |
| Epoetin alfa injection (Procrit) for anemia | 9,920 | $6 | $33 |
| Dexamethasone injection (steroid) | 4,082 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,681 | $1 | $4 |
| Drug injection, under skin or into muscle | 1,037 | $10 | $52 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 703 | $21 | $92 |
| Administration of chemotherapy into vein, 1 hour or less | 628 | $94 | $414 |
| Office visit, established patient (20-29 min) | 569 | $63 | $281 |
| Injection, carboplatin, 50 mg | 542 | $2 | $10 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 468 | $80 | $518 |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 444 | $94 | $544 |
| Injection of additional new drug or substance into vein | 407 | $11 | $52 |
| Hospital follow-up visit, moderate complexity | 324 | $60 | $233 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 274 | $46 | $204 |
| Administration of chemotherapy into vein, each additional hour | 269 | $21 | $89 |
| Office visit, established patient (30-39 min) | 249 | $92 | $396 |
| Injection, diphenhydramine hcl, up to 50 mg | 217 | $1 | $5 |
| Administration of additional new drug or substance into vein, 1 hour or less | 192 | $48 | $203 |
| Unclassified drugs | 176 | $1 | $2 |
| Injection, zoledronic acid, 1 mg | 160 | $6 | $39 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 157 | $24 | $126 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 151 | $15 | $65 |
| Administration of additional new drug or substance into vein using push technique | 121 | $39 | $175 |
| New patient office visit, complex (60-74 min) | 119 | $153 | $682 |
| Initial hospital admission, high complexity | 112 | $131 | $563 |
| Infusion into a vein for hydration, 31-60 minutes | 106 | $24 | $103 |
| Infusion, normal saline solution, 250 cc | 81 | $1 | $3 |
| Irrigation of implanted venous access drug delivery device | 72 | $15 | $82 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 70 | $1 | $8 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 66 | $1 | $5 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 56 | $14 | $62 |
| Urinalysis, manual | 45 | $3 | $10 |
| New patient office visit (45-59 min) | 42 | $117 | $526 |
| Hospital follow-up visit, high complexity | 39 | $91 | $335 |
| Application of on-body injector for under skin injection | 34 | $14 | $55 |
| Drawing of blood for a medical problem | 28 | $70 | $306 |
| Telephone medical discussion with physician, 5-10 minutes | 25 | $36 | $170 |
| Injection of drug or substance into vein | 15 | $28 | $118 |
| Office visit, established patient, complex (40-54 min) | 13 | $131 | $586 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 12 | $121 | $559 |
| Injection, morphine sulfate, up to 10 mg | 12 | $3 | $12 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
44.3% high complexity
54.7% medium
1.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$37,468
Total received (2018-2024)
Avg $5,353/year across 7 years
Top 7% in TX for optician
111
Companies
1,696
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$30,951 (82.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$4,961 (13.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,556 (4.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$5,944
2023$6,170
2022$7,058
2021$5,029
2020$3,683
2019$4,758
2018$4,827
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$2,438
E.R. Squibb & Sons, L.L.C.
$2,239
Exelixis Inc.
$1,829
Novartis Pharmaceuticals Corporation
$1,689
PFIZER INC.
$1,557
GENZYME CORPORATION
$1,515
Daiichi Sankyo Inc.
$1,504
Amgen Inc.
$1,424
Rigel Pharmaceuticals, Inc.
$1,215
McKesson Specialty Care Distribution, LLC
$1,201
Aveo Pharmaceuticals, Inc.
$1,163
Astellas Pharma US Inc
$1,117
Merck Sharp & Dohme LLC
$993
Celgene Corporation
$988
AstraZeneca Pharmaceuticals LP
$899
Genentech USA, Inc.
$809
Seagen Inc.
$807
Merck Sharp & Dohme Corporation
$703
Lilly USA, LLC
$638
Eisai Inc.
$592
Incyte Corporation
$575
GlaxoSmithKline, LLC.
$539
Teva Pharmaceuticals USA, Inc.
$466
Alexion Pharmaceuticals, Inc.
$451
Boehringer Ingelheim Pharmaceuticals, Inc.
$426
Gilead Sciences, Inc.
$390
Blueprint Medicines Corporation
$381
Bayer HealthCare Pharmaceuticals Inc.
$341
Janssen Scientific Affairs, LLC
$310
ARRAY BIOPHARMA INC
$299
Karyopharm Therapeutics Inc.
$295
Foundation Medicine, Inc.
$278
Takeda Pharmaceuticals U.S.A., Inc.
$276
EMD Serono, Inc.
$273
Regeneron Healthcare Solutions, Inc.
$269
Ipsen Biopharmaceuticals, Inc
$265
Apellis Pharmaceuticals, Inc.
$250
COMSORT, Inc
$250
Kite Pharma, Inc.
$244
Kyowa Kirin, Inc.
$232
Janssen Pharmaceuticals, Inc
$217
BeiGene USA, Inc.
$208
Seattle Genetics, Inc.
$189
Athenex Pharmaceutical Division, LLC
$175
ADC Therapeutics America, Inc.
$172
ABBVIE INC.
$172
JAZZ PHARMACEUTICALS INC.
$169
Bayer Healthcare Pharmaceuticals Inc.
$169
Pharmacyclics LLC, An AbbVie Company
$156
PUMA BIOTECHNOLOGY, INC.
$146
Heron Therapeutics, Inc.
$143
Deciphera Pharmaceuticals Inc.
$141
Tempus AI, Inc
$136
EISAI INC.
$131
Sobi, Inc
$130
SOBI, INC
$129
AVEO Pharmaceuticals, Inc.
$117
Dova Pharmaceuticals
$105
Puma Biotechnology, Inc.
$103
Intuitive Surgical, Inc.
$99
SERVIER PHARMACEUTICALS LLC
$99
SANOFI-AVENTIS U.S. LLC
$98
Taiho Oncology, Inc.
$97
Sumitomo Pharma America, Inc.
$95
SpringWorks Therapeutics, Inc.
$92
Immunocore Limited
$91
Jazz Pharmaceuticals Inc.
$84
PharmaEssentia USA Corporation
$84
TAIHO ONCOLOGY, INC.
$81
Alnylam Pharmaceuticals Inc.
$79
Coherus Biosciences Inc.
$76
TESARO, Inc.
$66
Genmab U.S., Inc.
$64
Stemline Therapeutics Inc.
$64
AbbVie, Inc.
$55
AMAG Pharmaceuticals, Inc.
$55
Sun Pharmaceutical Industries Inc.
$55
Verastem, Inc.
$54
Myovant Sciences Inc.
$52
Epizyme, Inc.,
$50
Servier Pharmaceuticals LLC
$50
Mylan Institutional Inc.
$43
MorphoSys, US Inc.
$40
Pharmacosmos Therapeutics Inc.
$40
Octapharma USA, Inc.
$40
Myriad Genetic Laboratories, Inc.
$39
TG THERAPEUTICS, INC.
$38
Mirati Therapeutics, Inc.
$37
TerSera Therapeutics LLC
$33
AbbVie Inc.
$32
Lexicon Pharmaceuticals, Inc.
$31
Immunomedics, Inc.
$29
Clovis Oncology, Inc.
$29
Tolmar, Inc.
$29
Midatech Pharma US Inc
$29
Organon LLC
$27
EUSA Pharma (US) LLC
$26
Acceleron Pharma, Inc.
$25
Agios Pharmaceuticals, Inc.
$25
G1 Therapeutics, Inc.
$23
Adaptive Biotechnologies Corporation
$23
Global Blood Therapeutics, Inc.
$22
Acrotech Biopharma LLC
$22
Spectrum Pharmaceuticals Inc.
$18
Pharming Healthcare, Inc.
$17
Tactile Systems Technology Inc
$17
Pharmacyclics LLC, an AbbVie Company
$13
Radius Health, Inc.
$12
Medtronic USA, Inc.
$12
R-Pharm US LLC
$11
Sandoz Inc.
$11
Top 3 companies account for 17.4% of total payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · BALVERSA · BAVENCIO · BENDEKA · BENLYSTA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · CABLIVI · CABOMETYX · CARVYKTI · CHANTIX · CINVANTI · COSELA · CREON · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · DOPTELET · Da Vinci Surgical System · Doptelet · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · ELZONRIS · EMEND · EMPLICITI · ENHERTU · ENJAYMO · ERLEADA · EVENITY · Empaveli · Enhertu · Epkinly · Erivedge · Erleada · FARESTON · FERAHEME · FOTIVDA · FOUNDATIONONE · FOUNDATIONONE CDX · FRUZAQLA · Fabhalta · Flexitouch Plus · GAVRETO · GAZYVA · GILOTRIF · GIVLAARI · Gazyva · Gelclair · HEMADY · HERZUMA · HTX-011 · HYQVIA · IBRANCE · ICLUSIG · IDHIFA · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Inrebic · Ixempra · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kadcyla · Kyprolis · LEQVIO · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MYLOTARG · MYRISK · Monoferric · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Odomzo · Ogivri · Onivyde · Orserdu · PADCEV · PANZYGA · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · Padcev · Perjeta · Pomalyst · Poteligeo · Prolia · QINLOCK · REBLOZYL · RETEVMO · ROLVEDON · RUCONEST · RYBREVANT · RYDAPT · Reblozyl · Revlimid · Rezlidhia · Rubraca · SANCUSO · SARCLISA · SCEMBLIX · SHINGRIX · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · Somatuline Depot · Stivarga · Sylvant · TAGRISSO · TASIGNA · TAVNEOS · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Tecentriq · Tibsovo · Trodelvy · Tymlos · UKONIQ · ULTOMIRIS · Udenyca · Ultomiris · VECTRIS · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Venclexta · Vyloy · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZIEXTENZO · ZYTIGA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (83%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 7% for optician in TX.
Equivalent to $18 per 100 Medicare services performed
Geographic Context
Opticians within 10 mi
51
Per 100K population
14.5
County median income
$66,021
Nearest hospital
CORPUS CHRISTI MEDICAL CENTER,THE
3.0 mi
3.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Mahmood is a mixed practice specialist, with above-average Medicare volume (top 0% in TX), and high industry engagement (low-engagement, top 7%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Mahmood experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Mahmood performed 64,770 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mahmood receive payments from pharmaceutical companies?
Yes. Dr. Mahmood received a total of $37,468 from 111 companies across 1,696 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mahmood's costs compare to other opticians in Corpus Christi?
Dr. Mahmood's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mahmood) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Corpus Christi
Browse opticians in Corpus Christi ranked by procedure volume and transparency data.
Highest volume
Top Opticians in TX
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in TX
Which TX opticians receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Exelixis Inc. Payments to Doctors
See all physicians who received payments from Exelixis Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology